Overview

Public BiotechPhase 4LSDketaminepsilocybin

Biotech advancing ketamine therapies including FDA-approved KETARx and PharmaPatch microneedle delivery platform. Developing long-acting injectable ketamine for neuropsychiatric indications.

Visit Website

Toronto, Canada

$15M
Market Cap
2020
Founded
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline(4)

Unknown·N/A·LSD

Investigating Lysosomal Storage Diseases in Minority Groups

Lysosomal Storage Disorders
NCT02120235
Not Yet Recruiting·Phase 4·ketamine

An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyperactive Delirium

Esketamine combined with dexmedetomidineDexmedetomidine
NCT07377981
Unknown·Phase 4·ketamine

Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma

EsketamineHepatocellular Carcinoma
NCT05416073
Unknown·Early Phase 1·psilocybin

A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients

Psilocybin-assisted therapy within a community of practice model (group administered)End of Life
NCT05958758